Tissue dissection, even in large-scale commercial labs, remains a manual, labor-intensive process at risk of error and cross contamination. “The Xyall solution provides the missing link for customers,” explained Du Pree. “With new therapies coming to the market, and transformative technologies in PCR and next generation sequencing, precision medicine is being revolutionized – providing physicians and patients with the highest quality information about their health. However, tissue dissection to enable molecular profiling is still a labor intense, subjective process. Our pioneering technology transforms how this is done – delivering greater accuracy, consistency and overall improved quality control.”
Alongside the new large-scale, industrial system, Xyall is developing a smaller, table-top version for hospital-based molecular pathology laboratories. Based on the same technology, the company expects to have this second system commercially available in Q1 2022. Mr Du Pree added: “Worldwide shortages of experienced pathology staff are already putting labs under pressure. The Xyall solution will address this, helping customers to make more efficient use of existing, and increasingly scarce, staffing levels.” Current practice involves manually pen-marking Regions of Interest (ROIs) on Hematoxylin & Eosin (H&E) stained slides. Using visual assessment, lab technicians then translate these ROIs into dissection slides, manually scraping the tissue and placing it in small containers.
Xyall is headquartered in Eindhoven, The Netherlands, and was founded in August 2018 by Guido du Pree and Hans van Wijngaarden. They are both advocates of precision medicine and worked together at Philips Healthcare as part of the senior management team developing the company’s global digital pathology business.
Source: Xyall BV